A randomized phase III trial of denosumab before curettage for giant cell tumor of bone. JCOG1610.
Hiroshi UrakawaAkihito NaganoRyunosuke MachidaKazuhiro TanakaTomoko KataokaYuta SekinoYoshihiro NishidaMitsuru TakahashiToshiyuki KunisadaMasanori KawanoYukihiro YoshidaTatsuya TakagiKenji SatoToru HirumaHiroshi HatanoSatoshi TsukushiAkio SakamotoToshihiro AkisueKoji HiraokaToshifumi OzakiPublished in: Japanese journal of clinical oncology (2022)
In terms of relapse-free survival, the superiority of preoperative denosumab was not observed in patients with giant cell tumor of bone without possible post-operative large bone defect.